|
Palo Alto, CA, January 7, 2008- Telik, Inc. (Nasdaq:
TELK) announced that company management will provide a corporate overview at the 26 th Annual JPMorgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2008 at 7:30 a.m. Pacific time (10:30 a.m. Eastern time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA®, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA™, which is in clinical development for the treatment of myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates.
###
Contact:
Patricia P. Frias
Corporate Communications
Telik, Inc.
Tel: 650 845 7927
Email: pfrias@telik.com
Go to: 2008 Press Releases
2007
Press Releases
2006
Press ReleasesEvents |
TELIK ANNOUNCES PRESENTATION AND WEBCAST AT JPMORGAN HEALTHCARE CONFERENCE
